Orphazyme A/S :Has Decided To Adjust Its Outlook For 2022.Change Is Driven By Separation Of Activities Into Continuing And Discontinued Operations.Expect To End 2022 With More Than Dkk 30 Million In Cash And Equivalents.For Full-Year 2022, We Anticipate A Loss From Continuing Operations In Range Dkk 40 Million - 45 Million.For Full-Year 2022, We Anticipate A Positive Result From Discont Operations Relating To The Sale Of Assets To Kempharm Of Dkk 87.4 Million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments